Navigation Links
New Drug May Help Combat Alzheimer's
Date:8/6/2008

Rapid improvement in verbal abilities, word finding, and aphasia in Alzheimer's disease and related forms of dementia following initiation of a new immune treatment is reported. These findings may be related to immune regulation of brain function, providing an exciting new area for Alzheimer research.

Los Angeles, CA (PRWEB) August 5, 2008 -- Rapid improvement of aphasia and word-finding difficulties, beginning within minutes of administration of an immune molecule, was presented last week at ICAD 2008(1), the world's leading forum on dementia research. Aphasia means difficulty or inability to use or understand language, causing problems with speech, reading, or writing and interfering with the daily activities of living. Disruption of language function, such as the ability to find words, is a common symptom in advancing Alzheimer's disease, and constitutes an enormous unmet medical need.

This report, also recently published in the Medscape Journal of Medicine(2), extends and confirms similar findings from a prospective, six month, 12 patient pilot study recently published in BMC Neurology(3), and additional reports in the Journal of Neuroinflammation(4) and Current Alzheimer Research(5). Each of these peer-reviewed studies focuses on the effects of perispinal administration of etanercept in dementia. Etanercept is an immune molecule which inactivates excess levels of an immune cytokine called tumor necrosis factor (TNF). This use of perispinal etanercept for dementia and Alzheimer's is beyond the FDA label (off-label). Etanercept is FDA-approved for treating certain forms of arthritis and a skin disorder in both children and adults.

TNF is a critical component of the brain's immune system which finely regulates the transmission of neural impulses between brain cells. The lead author of this study, Edward Tobinick MD(6), hypothesized that in Alzheimer's and related forms of dementia, such as primary progressive aphasia (PPA), elevated levels of TNF interfere with brain function, and could respond to treatment with perispinal etanercept. Rapid improvement in impaired speech, beginning within minutes, seems to be a unique effect of perispinal etanercept, and illustrates the existence of rapidly reversible TNF-dependent brain mechanisms in Alzheimer's disease and primary progressive aphasia.

Rapid improvement in cognition in patients with Alzheimer's following perispinal etanercept has also been recently reported (3,4,5). These rapid effects are thought to be due to TNF's novel role as a gliotransmitter regulating synaptic transmission (communication between brain cells), a physiologic function of TNF only recently recognized.

These new articles provide further evidence, in addition to accumulating genetic, epidemiologic, and basic science data (reviewed in references 3, 4, and 5), that excess TNF is a therapeutic target in Alzheimer's disease and related forms of dementia, and provide an exciting new direction for research.

Further information, including links to the published articles and videos of actual patient response, are available on the Web site of the Institute for Neurological Research(INR®), a private medical group, inc., at www.nrimed.com. Perispinal administration of etanercept for the treatment of Alzheimer's disease and selected additional neurological disorders is a patented invention of the INR; protected by U.S. patent 7,214,658, assigned to TACT IP, LLC and licensed to the INR, and additional issued and pending U.S. and international patents. For a further description of the attached video, please see the Medscape J Med. 2008; 10(6): 135. Physician training is available; please contact the INR for further information.

The new articles are open access, and available directly at the following links:

References:
1. Perispinal etanercept produces rapid improvement in primary progressive aphasia: Identification of a novel, rapidly reversible TNF-mediated pathophysiologic mechanism. Abstract 421, presented July 30, 2008 at ICAD 2008, Chicago, Illinois.
2. Perispinal etanercept produces rapid improvement in primary progressive aphasia: Identification of a novel, rapidly reversible TNF-mediated pathophysiologic mechanism, Neurology and Neurosurgery Clinical Cases, Medscape J Med. 2008; 10(6): 135.
3. Tobinick, E.L. and H. Gross, Rapid improvement in verbal fluency and aphasia following perispinal etanercept in Alzheimer's disease. BMC Neurol, 2008. 8(1): p. 27.
4. Tobinick, E.L. and H. Gross, Rapid cognitive improvement in Alzheimer's disease following perispinal etanercept administration. J Neuroinflammation, 2008. 5: p. 2.
5. Tobinick, E., Perispinal etanercept for treatment of Alzheimer's disease. Curr Alzheimer Res, 2007. 4(5): p. 550-2.
6. Edward Tobinick MD is medical director of the Institute for Neurological Research(INR®), a private medical group, inc., in Los Angeles, California.

###

Read the full story at http://www.prweb.com/releases/2008/08/prweb1175274.htm


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved

Related medicine news :

1. New Website Launches Healthy Vending in Schools Nationwide to Help Combat Childhood Obesity
2. Video and Photo: U.S. Department of Health & Human Services and Ad Council Join NFL to Combat Childhood Obesity
3. Blue Cross and Partners to Host Combat Stress Conference for Minnesotas Health Care Professionals
4. Lilly Grant to VA Will Enhance Services for Returning Combat Veterans
5. Pediatricians Awarded for Innovative Approaches to Combat Childhood Obesity
6. Key Cleaning Solutions Products Utilized to Combat Community Acquired - MRSA (CA-MRSA) Are Succeeding In Killing Superbugs Where Normal Cleaning Practices and Products Are Not
7. Georgetown leads major effort to combat disparities in DC stroke care
8. Polar Joins Alliance to Combat Childhood Obesity
9. States Largest Medicaid Managed Care Plan Offering Training to Combat West Virginia Obesity Epidemic
10. Committee to Reduce Infection Deaths Applauds Senator Durbins Hospital Infection Legislation, but Suggests Some Crucial Additions in Order to Combat Soaring MRSA Rates
11. Food tricks that combat sneaky, creepy Halloween treats
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... 24, 2016 , ... Those who have experienced traumatic events may suffer from ... avenues, such as drug or alcohol abuse, as a coping mechanism. To avoid this ... coping following a traumatic event. , Trauma sufferers tend to feel a range of ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, ... treatment. Dr. Cheng has extensive experience with all areas of orthodontics, including robotic ... osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... proud to recognize Dr. Barry M. Weintraub as a prominent plastic surgeon and ... women in the world, and the most handsome men, look naturally attractive. Plastic ...
(Date:6/24/2016)... ... June 24, 2016 , ... Today, MTI-GlobalStem, a provider of ... other difficult to transfect cells, announces its launch of the PluriQ™ G9™ Gene ... System is a complete system for culturing and transfecting human pluripotent stem ...
(Date:6/24/2016)... ... June 24, 2016 , ... Today, InhaleLabs.com (Inhale) offilially launched its ... by matching users with high quality water pipes within an ideal price range. The ... Inhale was founded by two brothers, Nick and Mike Hunter, who use medical cannabis ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 23, 2016 , , , ... 7, 2016 , , , , LOCATION: , , , ... , , , EXPERT PANELISTS:  , , , Frost & Sullivan,s ... Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and Unmesh Lal, Program ... global pharmaceutical industry is witnessing an exceptional era. Several new demand ...
(Date:6/23/2016)... 2016 The vast majority of dialysis patients ... Treatments are usually 3 times a week, with treatment ... travel time, equipment preparation and wait time.  This regimen ... for patients who are elderly and frail.  Many elderly ... rehabilitation centers for some duration of time. ...
(Date:6/23/2016)... 23, 2016 Leading BioSciences Inc., a ... conditions resulting from a breakdown of the mucosal ... Greg Doyle as chief executive officer. Mr. ... management team and board of directors, previously served ... He will provide continued leadership and strategic direction ...
Breaking Medicine Technology: